Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice

Nature Neuroscience

Volumn 5, Issue 12, 2002, Pages 1288-1293

  Tan, Jun ^a   Town, Terrence ^a   Crawford, Fiona ^a   Mori, Takashi ^a   DelleDonne, Anthony ^a   Crescentini, Robert ^a   Obregon, Demian ^a   Flavel, Richard A ^b   Mullan, Michael J ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CD40 ANTIGEN; CD40 LIGAND; TAU PROTEIN;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; CONTROLLED STUDY; LIGAND BINDING; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SENILE PLAQUE; TRANSGENIC MOUSE; VALIDATION PROCESS; WILD TYPE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIGENS, CD40; ASTROCYTES; BRAIN; CD40 LIGAND; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; GLIOSIS; MALE; MICE; MICE, KNOCKOUT; MICROGLIA; NEURONS; SENILE PLAQUES; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0036900076     PISSN: 10976256     EISSN: None     Source Type: Journal    
DOI: 10.1038/nn968     Document Type: Article

References (35)

1. Selkoe, D. J. Alzheimer's disease: Genes, proteins and therapy. Physiol. Rev. 81, 741-766 (2001).
2. McGeer, E. G. & McGeer, P. L. The importance of inflammatory mechanisms in Alzheimer disease. Exp. Gerontol. 33, 371-378 (1998).
3. Rogers, J. et al. Inflammation and Alzheimer's disease pathogenesis. Neurobiol. Aging 17, 681-686 (1996).
4. Itagaki, S., McGeer, P. L., Akiyama, H., Zhu, S. & Selkoe, D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J. Neuroimmunol. 24, 173-182 (1989).
5. Giulian, D. Microglia and the immune pathology of Alzheimer disease. Am. J. Hum. Genet. 65, 13-18 (1999).
6. Barger, S. W. & Harmon, A. D. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 388, 878-881 (1997).
7. Meda, L. et al. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 374, 647-650 (1995).
8. Grewal, I. S. & Flavell, R. A. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 16, 111-135 (1998).
9. Nguyen, V. T, Walker, W. S. & Benveniste, E. N. Post-transcriptional inhibition of CD40 gene expression in microglia by transforming growth factor-beta. Eur. J. Immunol. 28, 2537-2548 (1998).
10. Tan, J. et al. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science 286, 2352-2355 (1999).
11. Calingasan, N. Y., Erdely, H. A. & Altar, C. A. Identification of CD40 ligand in Alzheimer's disease and in animal models of Alzheimer's disease and brain injury. Neurobiol. Aging 23, 31-39 (2002).
12. Togo, T. et al. Expression of CD40 in the brain of Alzheimer's disease and other neurological diseases. Brain Res. 885, 117-121 (2000).
13. Hsiao, K. et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99-102 (1996).
14. Irizarry, M. C., McNamara, M., Fedorchak, K., Hsiao, K. & Hyman, B.T. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but noneuronal loss in CA1. Neuropathol. Exp. Neurol. 56, 965-973 (1997).
15. Holcomb, L. et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4, 97-100 (1998).
16. Schonbeck, U., Sukhova, G. K., Shimizu, K., Mach, F. & Libby, P. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc. Natl. Acad. Sci. U S A 97, 7458-7463 (2000).
17. Schmidt, M. L., Lee, V. M. & Trojanowski, J. Q. Relative abundance of tau and neurofilament epitopes in hippocampal neurofibrillary tangles. Am. J. Pathol. 136, 1069-1075 (1990).
18. Ball, M. J. et al. A new definition of Alzheimer's disease: A hippocampal dementia. Lancet 1, 14-16 (1985).
19. Luo, Y. et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat. Neurosci. 4, 231-232 (2001).
20. Tan, J. et al. CD40 is expressed and functional on neuronal cells. EMBO J. 21, 643-652 (2002).
21. Thinakaran, G., Teplow, D.B., Siman, R., Greenberg, B. & Sisodia, S.S. Metabolism of the "Swedish" amyloid precursor protein variant in neuro2a (N2a) cells. Evidence that cleavage at the "beta-secretase" site occurs in the golgi apparatus. J. Biol. Chem. 271, 9390-9397 (1996).
22. Schonbeck, U. et al. Ligation of CD40 activates interleukin-1beta-converting enzyme (caspase-1) activity in vascular smooth muscle and endothelial cells and promotes elaboration of active interleukin 1beta. J. Biol. Chem. 272, 19569-19574 (1997).
23. Mach, F. et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for CD40-CD40 ligand signaling in atherosclerosis. Proc. Natl. Acad. Sci. U S A 94, 1931-1936 (1997).
24. Piguet, P. F. et al. Role of CD40-CD40L in mouse severe malaria. Am. J. Pathol. 159, 733-742 (2001).
25. DeMattos, R. B. et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U S A 98, 8850-8855 (2001).
26. DeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M. & Holtzman, D. M. Brain to plasma amyloid-beta efflux: A measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295, 2264-2267 (2002).
27. Schenk D. et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177 (1999).
28. Wilcock, D. M. et al. Number of Abeta inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. DNA Cell Biol. 20, 731-736 (2001).
29. DiCarlo G. et al. Intrahippocampal LPS injections reduce Abeta load in APP+PS1 transgenic mice. Neurobiol. Aging 22, 1007-1012 (2001).
30. Qiao, X., Cummins, D. J. & Paul, S. M. Neuroinflammation-induced acceleration of amyloid deposition in the APPV717F transgenic mouse. Eur. J. Neurosci. 14, 474-482 (2001).
31. Lim, G. P. et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 20, 5709-5714 (2000).
32. Lim, G. P. et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 21, 8370-8377 (2001).
33. Jantzen, P. T. et al. Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenitin-1 transgenic mice. J. Neurosci. 22, 2246-2256 (2002).
34. Xu, J. et al. Mice deficient for the CD40 ligand. Immunity 1, 423-431 (1994).
35. Johnson-Wood, K. et al. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl. Acad. Sci. USA 94, 1550-1555 (1997).